Litcius/Paper detail

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy

Gerard Morton, Merrylee McGuffin, Hans T. Chung, Chia‐Lin Tseng, Joelle Helou, Ananth Ravi, Patrick Cheung, Ewa Szumacher, Stanley K. Liu, William Chu, Liying Zhang, Alexandre Mamedov, Andrew Loblaw

2020Radiotherapy and Oncology129 citationsDOI

Topics & Concepts

BrachytherapyProstate cancerMedicineProstateRandomized controlled trialUrologyOncologyFraction (chemistry)Nuclear medicineInternal medicineCancerRadiation therapyChemistryOrganic chemistryProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchAdvanced Radiotherapy Techniques
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy | Litcius